Yahoo Web Search

  1. Ads
    related to Leukemia
  1. Bristol-Myers' (BMY) Q3 Earnings & Revenues Beat Estimates

    Zacks via Yahoo FinanceOct 31 15:37 PM

    Bristol-Myers Squibb Company BMY reported better-than-expected results for the third quarter of 2019 on stellar performance of its blood thinner drug, Eliquis. Shares were down in pre-market ...

  2. Revenues increased year-over-year, driven by a strong uptake of Tibsovo in the frontline and relapsed/refractory acute myeloid leukemia (AML) settings. Agios’ first wholly owned drug ...

  3. ImmunoGen (IMGN) Q3 Earnings & Sales Beat, Shares Rally

    Zacks via Yahoo FinanceNov 04 16:54 PM

    ImmunoGen, Inc. IMGN reported loss of 15 cents per share for the third quarter of 2019, narrower than the Zacks Consensus Estimate of a loss of 19 cents and the year-ago loss of 31 cents. Revenues ...

  4. AbbVie Inc. ABBV delivered better-than-expected third-quarter 2019 earnings and revenues. AbbVie reported earnings of $2.33 per share in the third quarter, beating the Zacks Consensus Estimate ...

  5. AbbVie Inc’s ABBV flagship product, Humira, has witnessed declining sales in the past couple of quarters given the launch of biosimilars in international markets, especially Europe. These launches ...

  6. Alzheimer's Drug May Resurrect Biogen's Growth

    GuruFocus.com via Yahoo FinanceOct 25 22:23 PM

    This past Tuesday, Biogen Inc. (NASDAQ:BIIB) announced it has changed its outlook regarding its trial-phase Alzheimer's drug aducanumab in light of new test results. Biogen is a pharmaceutical ...

  7. U.S. drugmaker Bristol-Myers Squibb Co reported higher-than-expected third-quarter profit on Thursday, helped by strong sales of blood thinner Eliquis, even as growth of its blockbuster cancer ...

  8. Earnings, clinical trial readouts and positive FDA verdicts catalyzed fairly robust performances by biotech stocks last week. Biogen Inc (NASDAQ: BIIB )'s about-face with respect to its Alzheimer's drug ...

  9. Pelosi Calls Pharma’s Bluff on Drug Prices

    Bloomberg via Yahoo FinanceOct 31 14:00 PM

    This doomsday argument has worked for decades, but House Speaker Nancy Pelosi’s drug-price negotiation legislation is putting it to the test. A Congressional Budget Office analysis finds that ...

  10. Celgene Corporation CELG reported adjusted earnings of $2.99 per share in third-quarter 2019, which beat the Zacks Consensus Estimate of $2.73 and increased from $2.29 a year ago. Moreover, ...

  1. Ads
    related to Leukemia